Filtered By:
Condition: Bleeding
Education: Education

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 134 results found since Jan 2013.

Effects of a Pharmacist-Led Educational Interventional Program on Electronic Monitoring-Assessed Adherence to Direct Oral Anticoagulants: A Randomized, Controlled Trial in Patients with Nonvalvular Atrial Fibrillation
In this study, the selection of DOACs was not randomized, and the lack of assessment of the association between adherence to DOACs and clinical outcomes was a limitation. Japan Registry of Clinical Trials (jRCT) indentifier: jRCTs031180142. (Clin Ther. 2022;44:XXX-XXX) © 2022 Elsevier Inc.PMID:36244853 | DOI:10.1016/j.clinthera.2022.09.011
Source: Clinical Therapeutics - October 16, 2022 Category: Drugs & Pharmacology Authors: Tsuyoshi Shiga Toshimi Kimura Noritoshi Fukushima Yuji Yoshiyama Kazunori Iwade Fumiaki Mori Yoichi Ajiro Shoji Haruta Yuichiro Yamada Emi Sawada Nobuhisa Hagiwara SMAAP-AF Investigators Source Type: research

What Causes Sudden Vision Loss?
Discussion Vision loss, whether chronic or acute, is distressing at any time for patients and families. Prompt evaluation and treatment are important as maintenance of any acuity and light or movement is considered paramount. Most vision loss is due to chronic problems and aging issues but the differential diagnosis is broad. For any age, but especially children, uncorrected refractive errors can cause problems in not only in childhood but throughout someone’s lifetime. Visual impairment for distance vision is considered mild if worse than 6/12 in meters = 20/40 in feet or 0.3 LogMAR and for moderate impairment is 6/...
Source: PediatricEducation.org - September 5, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Outcome disparities in patients with atrial fibrillation based on insurance plan and educational attainment: a nationwide, multicenter and prospective cohort trial
Conclusion Educational attainment was independently associated with all-cause mortality and ischaemic stroke in patients with AF, but adverse clinical outcomes were not related to the types of health insurance in Thailand. Trial registration number Thai Clinical Trial Registration; Study ID: TCTR20160113002.
Source: BMJ Open - August 10, 2022 Category: General Medicine Authors: Apiyasawat, S., Thongsri, T., Jongpiputvanich, K., Krittayaphong, R., for the COOL-AF Investigators Tags: Open access, Cardiovascular medicine Source Type: research

U.S. Task Force Reconsiders Daily Low-Dose Aspirin Use for Preventing Heart Attacks in Adults Over 60
Older adults without heart disease shouldn’t take daily low-dose aspirin to prevent a first heart attack or stroke, an influential health guidelines group said in preliminary updated advice released Tuesday. Bleeding risks for adults in their 60s and up who haven’t had a heart attack or stroke outweigh any potential benefits from aspirin, the U.S. Preventive Services Task Force said in its draft guidance. For the first time, the panel said there may be a small benefit for adults in their 40s who have no bleeding risks. For those in their 50s, the panel softened advice and said evidence of benefit is less clear....
Source: TIME: Health - October 12, 2021 Category: Consumer Health News Authors: Lindsey Taylor/AP Tags: Uncategorized healthscienceclimate Research wire Source Type: news

Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT2R2 score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol
Introduction The burden of atrial fibrillation (AF) in Thailand is high and associated with increased morbidity, mortality and healthcare costs. Vitamin K antagonists (eg, warfarin), commonly used for stroke prevention in patients with AF in Thailand, are effective but are often suboptimally controlled. We aim to evaluate the impact of an SAMe-TT2R2 score-guided strategy and educational intervention compared to usual care on anticoagulation control expressed by the time in therapeutic range (TTR) at 12 months, in anticoagulant-naïve Thai patients with AF. Methods and analysis Multicentre, open-label, parallel-grou...
Source: BMJ Open - October 11, 2021 Category: General Medicine Authors: Phrommintikul, A., Nathisuwan, S., Gunaparn, S., Krittayaphong, R., Wongcharoen, W., Sehmi, S., Mehta, S., Winkles, N., Brocklehurst, P., Mathers, J., Jowett, S., Jolly, K., Lane, D., Thomas, G. N., Lip, G. Y. H., TREATS-AF Study Group, Prasertwitayakij, Tags: Open access, Medical management Source Type: research

Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment
by Jiaxi Zhao, Hao Wang, Xue Li, Yang Hu, Vincent K. C. Yan, Carlos K. H. Wong, Yutao Guo, Marco K. H. Cheung, Gregory Y. H. Lip, Chung-Wah Siu, Hung-Fat Tse, Esther W. Chan BackgroundAdherence to oral anticoagulant therapy in patients with atrial fibrillation (AF) in China is low. Patient preference, one of the main reasons for discontinuation of oral anticoagulant therapy, is an unfamiliar concept in China. Methods and findingsA discrete choice experiment (DCE) was conducted to quantify patient preference on 7 attributes of oral anticoagulant therapy: antidote (yes/no), food –drug interaction (yes/no), frequency of blo...
Source: PLoS Medicine - August 26, 2021 Category: Internal Medicine Authors: Jiaxi Zhao Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - August 19, 2021 Category: International Medicine & Public Health Source Type: research

Stroke management in a Swiss community hospital - in close collaboration with a stroke centre
CONCLUSION: Our findings support further education of the population in recognition of stroke symptoms and assessment of cardiovascular risk factors according to guidelines. Telemedical cooperation with a local stroke centre can result in adequate quality of care in these patients.PMID:34098584 | DOI:10.4414/smw.2021.20490
Source: Swiss Medical Weekly - June 7, 2021 Category: General Medicine Authors: Rolf Erlebach Esther B ächli Esther Gerrits Mich èle Hess Source Type: research

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - April 8, 2021 Category: International Medicine & Public Health Source Type: research

Association between use of amiodarone for non-valvular atrial fibrillation and patient survival: from the prospective China Atrial Fibrillation Registry.
CONCLUSIONS: Our study indicated that amiodarone use was not significantly associated with a lower risk of 1-year all-cause mortality compared with a non-AAD strategy in "real-world" patients with NVAF. PMID: 33273373 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - December 1, 2020 Category: General Medicine Authors: Hou XX, He L, Du X, Wang GH, Dong JZ, Ma CS Tags: Chin Med J (Engl) Source Type: research

VAD 911: Process Improvement for First Responders Treating Ventricular Assist Device Patients
This study conducted an assessment of first responders generalized knowledge and self-reported competency regarding VAD use, provided an education course, and tested for improvement immediately after and 1 month postintervention. Two hundred thirty-six first responders participated from communities with known VAD patients. Responses indicated poor knowledge, experience, and competency. Twenty-one percent had seen a manufacturer training video, 26% had attended prior training, and 38% knew who to contact with a VAD emergency. Generalized knowledge of VAD therapy was poor with majority not understanding use of anticoagulatio...
Source: ASAIO Journal - November 1, 2020 Category: Medical Devices Tags: Adult Circulatory Support Source Type: research